Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Pfizer’s says its COVID pill is highly effective in high risk cases. Some people believe them despite their bad integrity reputation

Pfizer’s says its COVID pill is highly effective in high risk cases. Some people believe them despite their bad integrity reputation

The pharmaceutical company says it intends to ask for authorisation for the pill from international regulators.

Pfizer said on Friday that its experimental, easy-to-use antiviral pill for COVID-19 cut rates of hospitalisation and death by nearly 90 per cent in high-risk adults.

Currently all COVID-19 treatments require an IV or injection, except for in the United Kingdom where Merck’s COVID-19 pill was approved for use on Thursday. The UK became the first country in the world to give it authorisation.

Pfizer said it will ask the Food and Drug Administration (FDA) in the United States and international regulators to authorise its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results.

"We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90 per cent efficacy and 100 per cent protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.

Researchers worldwide have been racing to find a COVID-19 pill that can be taken at home to ease symptoms, speed-up recovery and reduce the burden on hospitals and doctors.

What did the results show?


Pfizer released the preliminary results of its study, which surveyed 775 adults on Friday.

Results showed patients taking the company's drug along with another antiviral had an 89 per cent reduction in their combined rate of hospitalisation or death after a month, compared to patients taking a placebo.

Fewer than 1 per cent of patients taking the drug needed to be hospitalised and no one died. In the comparison group, 7 per cent were hospitalised and there were seven deaths.

Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalisation due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days.

Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20 per cent.

An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit.

The data has not yet been published for peer review, the normal process for vetting new medical research.

How does it work?


The European Medicine Agency said last week that it started a rolling review of the oral antiviral medicine molnupiravir, produced by Merck.

While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions.

The Merck drug works by interfering with the coronavirus' genetic code, a novel approach to disrupting the virus.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionised the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The drug, which has not yet been named, was first identified during the SARS outbreak originating in Asia during 2003.

Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
Amazon Reaches Major Automation Milestone with Over One Million Robots
Extreme Heat Wave Sweeps Across Europe, Hitting Record Temperatures
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
Robots Compete in Football Tournament in China Amid Injuries
China Unveils Miniature Insect-Like Surveillance Drone
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Massive Anti-Government Protests Erupt in Belgrade
Iran Executes Alleged Israeli Spies and Arrests Hundreds Amid Post-War Crackdown
Hungary's Prime Minister Criticizes NATO's Role in Ukraine
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Hungarian Scientist to Conduct 30 Research Experiments on the International Space Station
NATO Members Agree to 5% Defense Spending Target by 2035
NATO Leaders Endorse Plan for Increased Defence Spending
U.S. Crude Oil Prices Drop Below $65 Amid Market Volatility
International Astronaut Team Launched to Space Station
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Iran Intensifies Crackdown on Alleged Mossad Operatives After Sabotage Claims
Trump Praises Iran’s ‘Very Weak’ Response After U.S. Strikes and Presses Israel to Pursue Peace
Oil Prices Set to Surge After US Strikes Iran
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Hungary Ranked Among the World’s Safest Travel Destinations for 2025
G7 Leaders Fail to Reach Consensus on Key Global Issues
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Shock Within Iran’s Leadership: Khamenei’s Failed Plan to Launch 1,000 Missiles Against Israel
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
×